ANCA Associated Vasculitis
Immunology
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
M&
Merck & Co.RAHWAY, NJ
1 programSubclinical Cytomegalovirus Reactivation in Acute ANCA-associated VasculitisN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
Travere TherapeuticsSparsentan
Merck & Co.Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis
Clinical Trials (2)
Total enrollment: 70 patients across 2 trials
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Start: Dec 2022Est. completion: Sep 2027
Phase 2Active Not Recruiting
Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis
Start: Apr 2022Est. completion: Dec 202570 patients
N/AActive Not Recruiting
Related Jobs in Immunology
Regulatory Affairs Manager(Immunology), Korea
AbbVie
Seoul, Seoul
12h ago
Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)
AbbVie
Remote
12h ago
Field Reimbursement Manager - Rheumatology - Seattle, WA (North)
Johnson & Johnson
Seattle, Washington, United States of America
Yesterday
$100K - $175K/yr
Senior Medical Science Liaison, Dermatology - Indianapolis
Johnson & Johnson
Indianapolis, Indiana, United States
Yesterday
$137K - $236K/yr
Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine
Johnson & Johnson
Detroit, Michigan, United States
Yesterday
Supply Chain and Procurement Controller
Ferring Pharmaceuticals
Hvidovre, Denmark
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space